Advertisement
Advertisement
CSBR
Champions Oncology, Inc.
4.79
USDSponsored
+0.03
+0.63%
Nov 06, 15:59 UTC -5
Closed
After-Market
4.85
+0.06
+1.25%
Champions Oncology, Inc. (CSBR) Earnings
CSBR Earnings Reports
Positive Surprise Ratio
CSBR beat 18 of 34 last estimates.
53%
Next Report
Date of Next Report
Dec 14, 2026
Estimate for Q2 27 (Revenue/ EPS)
$16.70M
/$0.02
Implied change from Q1 27 (Revenue/ EPS)
+9.66%
/-166.67%
Implied change from Q2 26 (Revenue/ EPS)
+11.04%
/--
Champions Oncology, Inc. earnings per share and revenue
On Sep 10, 2026, CSBR reported earnings of -0.03 USD per share (EPS) for Q1 27, missing the estimate of -0.01 USD, resulting in a -194.12% surprise. Revenue reached 15.23 million, compared to an expected 15.35 million, with a -0.76% difference. The market reacted with a +0.09% price change (close before vs. close after earnings).
Looking ahead to Q2 27, -- analysts forecast an EPS of 0.02 USD, with revenue projected to reach 16.70 million USD, implying an decrease of -166.67% EPS, and increase of 9.66% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Champions Oncology, Inc.'s earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Champions Oncology, Inc. reported EPS of -$0.03, missing estimates by -194.12%, and revenue of $15.23M, -0.76% below expectations.
How did the market react to Champions Oncology, Inc.'s Q1 2027 earnings?
The stock price moved up 0.09%, changed from $5.10 before the earnings release to $5.10 the day after.
When is Champions Oncology, Inc. expected to report next?
The next earning report is scheduled for Dec 14, 2026.
What are the forecasts for Champions Oncology, Inc.'s next earnings report?
Based on --
analysts, Champions Oncology, Inc. is expected to report EPS of $0.02 and revenue of $16.70M for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.